Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. (Q53463465)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

author name string

John Sarantopoulos

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Monica M Mita

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Michael J Birrer

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Lee D Cranmer

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Luis T Campos

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Xiaoping Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Penelope Bristow

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Hidekuni Kaito

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Vincent Strout

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

publication date

1 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Targeted oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

11

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

317-327

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Validation of HB-EGF and amphiregulin as targets for human cancer therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

The EGF receptor family: spearheading a merger of signaling and therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Expression of Heparin-Binding Epidermal Growth Factor-like Growth Factor in Pancreatic Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

HB-EGF is a potent inducer of tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrain

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Neuronal and glial expression of heparin-binding EGF-like growth factor in central nervous system of prenatal and early-postnatal rat.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Intranasal HB-EGF administration favors adult SVZ cell mobilization to demyelinated lesions in mouse corpus callosum

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

Heparin-binding EGF-like growth factor is required for synaptic plasticity and memory formation

1 reference

https://api.crossref.org/works/10.1007%2FS11523-015-0394-5

21 January 2018

IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased expression of integrins by heparin-binding EGF like growth factor in human esophageal cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26507836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-015-0394-5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26507836

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53463465&oldid=2212136228"